GlassScriptPhysician profile
Marie E Briden
NPI 1548235872
$1,869.45
in general payments reported to CMS, 2019-2025
19 companies · $73.61 in 2025
The $73.61 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.90 · 2020: $47.22 · 2021: $43.77 · 2022: $148 · 2023: $83.59 · 2024: $1,399 · 2025: $73.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,270 · Food and Beverage: $278 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,269.75 |
| Food and Beverage | $278.01 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $800.00 | 2024 | Eversense |
| Abbvie INC. | $520.47 | 2022-2024 | Rinvoq |
| Genzyme Corporation | $86.07 | 2021-2025 | |
| Bsn Medical INC | $69.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $68.31 | 2019-2024 | Libtayo, Dupixent |
| Amgen INC. | $49.70 | 2020-2025 | Otezla |
| Incyte Corporation | $32.98 | 2021-2025 | Opzelura |
| Allergan, INC. | $32.22 | 2020 | |
| Janssen Biotech, INC. | $28.74 | 2022 | |
| Arcutis Biotherapeutics, INC. | $27.30 | 2023-2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $26.94 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $24.11 | 2019 | |
| Biocon Biologics INC | $19.54 | 2025 | Yesintek |
| Biofrontera INC. | $16.13 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ascensia Diabetes Care US INC. | $13.99 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $13.75 | 2019 | |
| Leo Pharma INC. | $13.47 | 2023 | Adbry |
| Genentech USA, INC. | $13.03 | 2022 | |
| Lilly USA, LLC | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Briden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.